Cost effectiveness of empagliflozin in adult patients with chronic kidney disease in the Netherlands
Using empagliflozin in addition to SoC in adult patients with CKD is likely to be cost saving compared to the current SoC in the Netherlands, irrespective of diabetes status and albuminuria.
Authors
- Maarten Jacobus Postma (ORCID: https://orcid.org/0000-0002-6306-3653)
- Lisa A. de Jong (ORCID: https://orcid.org/0000-0001-8814-0670)
- Tanja Fens (ORCID: https://orcid.org/0000-0003-3995-447X)
- Maaike Weersma
- Cornelis Boersma
- Bart Slob (ORCID: https://orcid.org/0009-0008-9125-0190)
Institutions
- University Medical Center Groningen (NL)
- University of Groningen (NL)
- Universitas Airlangga (ID)
- Boehringer Ingelheim (Netherlands) (NL)
- Open University of the Netherlands (NL)
- Padjadjaran University (ID)
Publication Details
- Journal
- PLoS ONE
- Published
- 2024-12-10
- DOI
- https://doi.org/10.1371/journal.pone.0315509
- Citations
- 2
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.72
Funders
- Boehringer Ingelheim